21.   The agency cut the review time to six months from more than two and a half years.

22.   The act was renewed last year, and the industry expects review times and overall development times to drop even further, PhRMA officials said.

23.   The legislation is critical for the drug industry because it renews an expiring program that has already cut drug review times dramatically.

24.   The successful user fee act, which is set to expire in October, assesses fees on drug companies in return for faster review times at the FDA.

25.   They communicate just once a year when annual review time comes up.

26.   For drugs the FDA deems breakthrough medicines, it knocks the review time down to six months.